| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Healthtech Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 11 Month Change | -80.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.98% |
| 5 Year Change | n/a |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLTT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.9% |
| 1Y | n/a | 12.5% | 32.3% |
Return vs Industry: Insufficient data to determine how HLTT performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how HLTT performed against the US Market.
Price Volatility
| HLTT volatility | |
|---|---|
| HLTT Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HLTT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine HLTT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 18 | Jelena Olmstead | n/a |
Healthtech Solutions Inc., through its subsidiaries, operates as a life sciences company. It focuses on the development of wound care products for acute and chronic wounds, including a placental membrane allograft for burns and non-healing wounds, such as diabetic foot ulcers. The company also engages in the development of ultrasound imaging and artificial intelligence-based image analysis software for the applications in treatment of chest and musculoskeletal system.
Healthtech Solutions Inc. Fundamentals Summary
| HLTT fundamental statistics | |
|---|---|
| Market cap | US$10.31k |
| Earnings (TTM) | -US$3.04m |
| Revenue (TTM) | US$1.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs HLTT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLTT income statement (TTM) | |
|---|---|
| Revenue | US$1.69m |
| Cost of Revenue | US$123.86k |
| Gross Profit | US$1.56m |
| Other Expenses | US$4.61m |
| Earnings | -US$3.04m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did HLTT perform over the long term?
See historical performance and comparison